Rigel Reports Q3 2026 Revenues of $80.9 Million
Rigel Pharmaceuticals reported Q3 2026 revenues of $80.9 million, driven by net product sales including the newly launched VEPPANU and updated revenue guidance.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed